TY - JOUR
T1 - Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA)
T2 - A study to determine the effect of a structured SMBG intervention
AU - Scavini, Marina
AU - Bosi, Emanuele
AU - Ceriello, Antonio
AU - Giorgino, Francesco
AU - Porta, Massimo
AU - Tiengo, Antonio
AU - Vespasiani, Giacomo
AU - Bottalico, Davide
AU - Marino, Raffaele
AU - Parkin, Christopher
AU - Bonizzoni, Erminio
AU - Cucinotta, Domenico
PY - 2013
Y1 - 2013
N2 - Self-monitoring of blood glucose (SMBG) is a core component of diabetes management. However, the International Diabetes Federation recommends that SMBG be performed in a structured manner and that the data are accurately interpreted and used to take appropriate therapeutic actions. We designed a study to evaluate the impact of structured SMBG on glycemic control in non-insulin-treated type 2 diabetes (T2DM) patients. The Prospective, Randomized Trial on Intensive SMBG Management Added Value in Non-insulin-Treated T2DM Patients (PRISMA) is a 12-month, prospective, multicenter, open, parallel group, randomized, and controlled trial to evaluate the added value of an intensive, structured SMBG regimen in T2DM patients treated with oral agents and/or diet. One thousand patients (500 per arm) will be enrolled at 39 clinical sites in Italy. Eligible patients will be randomized to the intensive structured monitoring (ISM) group or the active control (AC) group, with a glycosylated hemoglobin (HbA1c) target of
AB - Self-monitoring of blood glucose (SMBG) is a core component of diabetes management. However, the International Diabetes Federation recommends that SMBG be performed in a structured manner and that the data are accurately interpreted and used to take appropriate therapeutic actions. We designed a study to evaluate the impact of structured SMBG on glycemic control in non-insulin-treated type 2 diabetes (T2DM) patients. The Prospective, Randomized Trial on Intensive SMBG Management Added Value in Non-insulin-Treated T2DM Patients (PRISMA) is a 12-month, prospective, multicenter, open, parallel group, randomized, and controlled trial to evaluate the added value of an intensive, structured SMBG regimen in T2DM patients treated with oral agents and/or diet. One thousand patients (500 per arm) will be enrolled at 39 clinical sites in Italy. Eligible patients will be randomized to the intensive structured monitoring (ISM) group or the active control (AC) group, with a glycosylated hemoglobin (HbA1c) target of
KW - Diabetes medication algorithm
KW - Patient empowerment
KW - Randomized clinical trial
KW - Self-monitoring of blood glucose
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=84885422646&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885422646&partnerID=8YFLogxK
U2 - 10.1007/s00592-011-0357-y
DO - 10.1007/s00592-011-0357-y
M3 - Article
C2 - 22189755
AN - SCOPUS:84885422646
SN - 0940-5429
VL - 50
SP - 663
EP - 672
JO - Acta Diabetologica
JF - Acta Diabetologica
IS - 5
ER -